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Abstract
Glasdegib is a Hedgehog pathway inhibitor. This ongoing, open-label, phase 2 study
(NCT01546038) evaluated glasdegib plus cytarabine/daunorubicin in patients with untreated
acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS). Patients received
glasdegib 100 mg orally, once daily in continuous 28-day cycles from day −3, with intravenous
cytarabine 100 mg/m2 on days 1-7 and daunorubicin 60 mg/m2 on days 1-3. Patients in remis-
sion then received consolidation therapy (2-4 cycles of cytarabine 1 g/m2 twice daily on days
1, 3, 5 of each cycle), followed by maintenance glasdegib (maximum 6 cycles). Primary endpoint
was complete remission (CR) in patients aged ≥55 years. Secondary endpoints included overall
survival (OS), safety and outcome by mutational status. Patients had a median (range) age of
64.0 (27-75) years, 60.0% were male, and 84.5% were white. In 69 evaluable patients, 46.4%
(80% confidence interval [CI]: 38.7-54.1) achieved investigator-reported CR. Among patients
≥55 years old (n = 60), 40.0% (80% CI 31.9-48.1) achieved CR. Among all 69 patients, median
OS was 14.9 (80% CI 13.4-19.3) months, with 12-month survival probability 66.6% (80% CI
58.5-73.4). The most common treatment-related adverse events (≥50% patients) were diarrhea
and nausea. There were no significant associations between mutational status (12 genes) and
clinical response, suggesting potential benefit across diverse molecular profiles. Glasdegib plus
cytarabine/daunorubicin was well tolerated and associated with clinical activity in patients with
untreated AML or high-risk MDS. A randomized phase 3 trial of glasdegib in combination with
chemotherapy (7 + 3 schedule) is ongoing.
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1 | INTRODUCTION
Acute myeloid leukemia (AML) is the most common acute leukemia in
adults, and incidence correlates with age. Older (>60 years) patients
with AML typically have poorer prognoses and outcomes compared
with younger patients, with response rates ≤50% to conventional
treatments frequently reported, and few patients survive >2 years.1–8
The Hedgehog (Hh) signaling pathway is critical for embryogene-
sis, and is typically repressed after birth.9–11 In normal tissue, Hh acti-
vation is dependent on the transmembrane protein Smoothened
(SMO).9–11 Hh ligand-binding results in the Patched receptor releasing
SMO, which then moves from an intracellular vesicle into the primary
cilium.9–12 Activated glioma (GLI)-associated proteins then translocate
to the nucleus and promote target gene transcription.9–12 Aberrations
in Hh signaling have been identified in a variety of human leukemias
and particularly in leukemia stem cells.10–14 Upregulation of Hh
pathway components is implicated in chemoresistant AML cell lines,
and pharmacologic inhibition of the Hh pathway results in decreased
multidrug resistance and P-glycoprotein expression in these
cells.10–12,15,16 Studies in transgenic mouse models of leukemia have
also supported a role for Hh signaling in disease progression.17–19 In
addition, overexpression of GLI1 is associated with relapse, drug
resistance, poor remission and reduced overall survival (OS) in
patients with AML.10,11
Glasdegib (PF-04449913) is an oral, small molecule inhibitor of
the Hh pathway component SMO.20–25 Glasdegib prevents the trans-
location of SMO into primary cilia and prevents SMO-mediated acti-
vation of downstream Hh targets.12,23,26 Previous studies have
reported glasdegib inhibition of SMO reduced the expression of key
intracellular leukemia stem cell regulators (eg, GLI2) and enhanced cell
cycle transit.23,27 These results and preclinical evidence that Hh inhibi-
tion may sensitize cells to cytarabine or azacitidine10,11,14,28 provided
rationale for evaluating glasdegib in combination with chemothera-
peutic agents to reduce resistance and leukemic persistence or
progression.
In an open-label, phase 1 study (ClinicalTrials.gov, NCT00953758)
of glasdegib in adult patients with myeloid malignancies who were
refractory, resistant, or intolerant to previous agents, treatment was
generally well tolerated and some preliminary clinical activity was
observed.25 The most common treatment-related adverse events (AEs)
included dysgeusia (28%), decreased appetite (19%) and alopecia
(15%).25 None of the 15 deaths reported were considered to be
treatment-related.25 In an open-label, phase 1B study (NCT01546038),
glasdegib was well tolerated in combination with low-dose cytarabine
(LDAC) or decitabine, or in combination with cytarabine/daunorubicin,
in patients with AML or high-risk myelodysplastic syndromes (MDS).29
The most common treatment-related nonhematologic AEs were mostly
grade 1-2. The recommended phase 2 dose was established as 100 mg
daily in combination with standard chemotherapy.29 In the phase
2 portion of the study (NCT01546038) in previously untreated
patients with AML or high-risk MDS, glasdegib plus LDAC improved
OS compared with LDAC alone; the improvement was consistent
among subgroups.26 Glasdegib plus LDAC was associated with an
acceptable safety profile.26
The objectives of this phase 2 study were to evaluate the efficacy
of glasdegib when administered in combination with standard cytara-
bine/daunorubicin induction (on a 7 + 3 schedule) and consolidation,
followed by maintenance therapy, in patients with previously
untreated AML or high-risk MDS.
2 | METHODS
2.1 | Study design
This was an open-label, phase 2, multicenter study of glasdegib in
combination with cytarabine/daunorubicin in patients with previously
untreated AML or high-risk MDS. The study was conducted globally
at 25 centers. The study was approved by an institutional review
board or independent ethics committee at each study center, and was
conducted in accordance with the study protocol, International Ethical
Guidelines for Biomedical Research Involving Human Subjects (2002),
Guidelines for Good Clinical Practice (1996), the Declaration of Hel-
sinki (1996 and 2008), and applicable local regulatory requirements
and laws. All patients provided written informed consent. The study is
registered on ClinicalTrials.gov (NCT01546038; Pfizer study number
B1371003).
2.2 | Patients
Patients ≥18 years old were registered using an Interactive Registra-
tion System. The study was designed specifically for older (≥55 years)
patients; however, up to 10 patients aged <55 years were permitted
to enter the study for exploratory purposes. After these 10 patients
were enrolled, enrollment was restricted to patients aged ≥55 years.
Patients had newly diagnosed or previously untreated AML (de novo
AML, AML evolving from an antecedent hematologic disease or MDS,
or AML secondary to previous cytotoxic or radiation therapy) or
refractory anemia with excess blast 2 high-risk MDS, according to the
World Health Organization 2008 classification.
Patients with MDS, as well as those with AML arising from MDS
or other antecedent hematologic disease, may have had one prior reg-
imen with a commercially available agent(s) for the treatment of prior
hematologic disease. Prior therapy for AML was not permitted.
Patients had to have adequate organ function, with an Eastern Coop-
erative Oncology Group performance status <2 in order to receive
intensive chemotherapy.
Patients were excluded if they had any of the following: t
(9;22) cytogenetic translocation, acute promyelocytic leukemia,
hyperleukocytosis (leukocytes ≥30 × 109/L) at screening (hydroxy-
urea or leukopheresis were allowed before and up to 1 week after
first dose of glasdegib for control of rapidly progressing leukemia),
or known active leukemia in the central nervous system. Other
exclusion criteria included: serum creatinine >1.3 mg/dL, severe
cardiac disease (eg, left-ventricular ejection fraction <45% by mul-
tiple gated acquisition or echocardiography at screening), or a
cumulative anthracycline dose equivalent of ≥250 mg/m2 of dau-
norubicin or ≥125 mg/m2 of idarubicin.
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2.3 | Study treatment
Patients received glasdegib 100 mg orally, once daily in continuous
28-day cycles. Patients received induction with glasdegib from day −3
in combination with intravenous daunorubicin 60 mg/m2 (on days
1-3) and continuous intravenous cytarabine 100 mg/m2 (on days 1-7).
If required, a second induction cycle could be initiated at the same
doses as early as day 21 of cycle 1. Patients achieving complete remis-
sion (CR) were eligible to receive consolidation therapy with 2-4
cycles of cytarabine 1 g/m2 twice daily on days 1, 3 and 5 of each
cycle. Following consolidation, single-agent glasdegib 100 mg admin-
istered daily continuously, as maintenance therapy, for a maximum of
6 cycles (1 cycle = 28 days) was permitted. Patients who completed
the maximum number of treatment cycles and demonstrated clinical
benefit were allowed to remain on therapy upon agreement between
the investigator and sponsor.
Study treatment continued until the patient withdrew consent,
developed unacceptable toxicity, or demonstrated either resistant dis-
ease during induction or disease progression/relapse after induction.
Patients could proceed to allogeneic stem cell transplant; those who
did were removed from study treatment and followed for survival.
The 100 mg glasdegib daily dose could be temporarily interrupted or
reduced to 50 mg to manage toxicity. After cycle 1, if a toxicity was
attributed to the backbone chemotherapy and not to glasdegib, che-
motherapeutics could be delayed or reduced, with continuation of
glasdegib. If a patient had a dose reduction for a study drug-related
toxicity, the dose was not to be re-escalated.
2.4 | Assessments
2.4.1 | Clinical activity
Efficacy endpoints were based on investigator assessment, using the
modified International Working Group criteria.30,31 Bone marrow
evaluations were performed on day 21 of induction cycle 1, and
thereafter at the investigator's discretion prior to the next cycle of
chemotherapy. If a second cycle of induction therapy was required, a
bone marrow evaluation was performed on day 21 of induction cycle
2. Patients underwent bone marrow evaluations on day 21 of the con-
solidation final cycle, day 1 of maintenance cycles 3 and 6. A bone
marrow aspirate was required at end of treatment regardless of when
the patient discontinued the trial, unless the end of treatment was
within 14 days of a prior evaluation. All aspirate collections were man-
datory unless deemed inappropriate by the investigator and agreed by
the sponsor. For the purposes of calculating response duration, bone
marrow collection dates were used as the start/stop dates. Patients
still in CR/CR with incomplete blood count recovery (CRi)/morpho-
logic leukemia-free state (MLFS) at the most recent bone marrow
assessment were censored at the end of treatment.
2.4.2 | Safety
Safety evaluations included physical examinations, laboratory tests,
12-lead electrocardiograms, and AEs, with monitoring graded by the
National Cancer Institute Common Terminology Criteria for Adverse
Events version 4.0.
2.4.3 | Pharmacokinetics
Patient blood samples were collected for pharmacokinetic (PK) analy-
sis of glasdegib at protocol-defined time points. Glasdegib plasma pre-
dose concentration (Ctrough) levels were estimated based on sparse PK
sampling data. Additional details of PK analyses can be found in the
Supporting Information Materials.
2.5 | Mutational analyses
Baseline central laboratory assessments included analysis of 12 genes
frequently mutated in patients with AML or MDS. Additional details
can be found in the Supporting Information Materials.
2.6 | Statistical analyses
The primary endpoint analyses for this study were based on patients
who were ≥55 years old. The primary endpoint was CR, with the final
analysis timing defined as deaths in at least 40 of 60 patients
≥55 years old. However, due to a lower than anticipated death rate, a
decision was made to declare the primary completion date and data
cut-off date as January 3, 2017, wherein 38 deaths were reported.
A key secondary endpoint was OS. Other secondary endpoints
included: disease-specific efficacy endpoints; the type, incidence,
severity, timing, seriousness and relatedness of AEs; corrected QT
(QTc) interval; glasdegib PK; and mutational analyses. Exploratory
endpoints included: CR in patients younger than 55 years and effi-
cacy endpoints based on cytogenetic risk. For AML, cytogenetic risk
was assessed using European Leukemia Net (ELN) Risk Criteria
2010.32 For MDS, the International Prognostic Scoring System
(IPSS) was used.33
The planned sample size was approximately 70 patients. The
focus of the primary analysis was patients aged ≥55 years, with
60 patients ≥55 years old providing ≥82% power to reject the null
hypothesis of CR rate of 54% (cytarabine/daunorubicin alone) if the
true CR rate of the combination with glasdegib is 68%. This allowed a
one-sided type I error rate of 10% under a binomial distribution and
one futility analysis at 2 months after the enrollment of the 30th
patient. Up to 10 patients <55 years old were to be enrolled for
exploratory purposes.
The full analysis set included all enrolled patients who received
at least one dose of study medication. The PK analysis population
included all treated patients who had at least one PK parameter esti-
mated. The baseline mutational analysis population included all trea-
ted patients evaluable for both baseline mutational status and
response.
Descriptive statistics were used throughout the study unless oth-
erwise stated. For the primary efficacy endpoint and binary efficacy
endpoints, point estimates and 80% confidence intervals (CI) were
provided; all were based on investigator assessment data. Time-to-
event endpoints were summarized using the Kaplan-Meier method.
Median event times and two-sided 80% CIs were provided. Statistical
analyses were performed using SAS version 9.4 (SAS Institute,
Cary, NC).
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3 | RESULTS
3.1 | Patients
A total of 71 patients aged ≥55 years (n = 61) or <55 years (n = 10)
were enrolled: 66 patients with AML and five patients with MDS;
69 patients (n = 60/9, aged ≥55/<55 years) were treated and
included in the full analysis set; two patients were enrolled, but not
treated. Of 69 patients who were treated, six (8.7%) completed treat-
ment and 63 (91.3%) patients discontinued treatment (Supporting
Information Figure S1). The main reasons for discontinuations from
study treatments were: insufficient clinical response (n = 29; 42.0%)
and “other” (n = 15; 21.7%), with the majority of “other” due to trans-
plantation (n = 12/15); 11 (15.9%) patients permanently discontinued
study treatments due to treatment-related AEs, which included neu-
trophil count decreased and pneumonitis (related to daunorubicin and
cytarabine); myocarditis (related to daunorubicin and glasdegib); inter-
mittent elevated alanine aminotransferase (ALT) (related to daunorubi-
cin, cytarabine and glasdegib); diarrhea (related to daunorubicin,
cytarabine and glasdegib) and nausea in one patient; gastrointestinal
bleeding and infectious enterocolitis in one patient; adenovirus infec-
tion; worsening muscle cramps; epigastric pain; atrial fibrillation; and
elevated aspartate aminotransferase and ALT in one patient.
Most patients were male (n = 43; 60.6%) and white (n = 60;
84.5%), with a median age of 64.0 (range 27-75) years. The majority
of patients had Eastern Cooperative Oncology Group performance
status 1 (n = 44; 62.0%) and good/intermediate cytogenetic risk (ie,
favorable, intermediate-I, or intermediate-II risk; n = 50; 70.4%)
(Supporting Information Table S1). Seven (9.9%) patients received
prior hypomethylating agents (decitabine or azacitidine).
The number of patients starting each cycle was: glasdegib induc-
tion, n = 69 (100.0%); re-induction cycle 2, n = 14 (20.3%); consolida-
tion, n = 26 (37.7%); and maintenance, n = 15 (21.7%). Of the
15 patients who received at least 1 cycle of maintenance therapy,
6 completed 6 cycles, 6 discontinued due to cytogenetic or morpho-
logical relapse, 2 discontinued due to AEs (grade 1-2 nausea/diarrhea;
grade 3 muscle spasms) and one patient refused further treatment
after receiving 11 cycles of maintenance. Following discontinuation of
the study treatment, 72.5% (n = 50) of patients received follow-up
systemic therapies, with the majority of patients (n = 39) receiving
chemotherapy (Supporting Information Table S2).
The median exposure to glasdegib was 48.0 (range 10-501) days.
The mean relative glasdegib dose intensity was 89.6% and the mean
relative chemotherapy dose intensities were 99.2% and 99.1% for
cytarabine and daunorubicin, respectively.
3.2 | Clinical activity
Of the 69 patients, 46.4% (80% CI 38.7-54.1) achieved CR (Table 1).
For the primary analysis, CR (80% CI) was reported in 40.0%
(31.9-48.1) of patients aged ≥55 years and 88.9% (75.5-100.0) in
patients aged <55 years; 37 (53.6% [80% CI 45.9-61.3]) patients
overall, 35 (54.7% [80% CI 46.7-62.7]) with AML and 2 (40.0% [80%
CI 11.9-68.1]) with MDS achieved CR/CRi (Supporting Information
Tables S3 and S4). The median (range) duration of CR was
94 (1-480) days in all patients and 103 (1-480) and 50 (1-268) days
in patients aged ≥55 years and <55 years, respectively. The median
(range) duration of CR, CRi, or MLFS across all patients was
53 (1-480) days. The number of patients censored for CR duration
was 16/24 (66.7%) and 5/8 (62.5%) in the groups aged ≥55 and <55
years, respectively.
Median OS was 14.9 (80% CI 13.4-19.3) months, with a
12-month survival probability of 66.6% (80% CI 58.5-73.4) (Figure 1).
Median OS (80% CI) in patients aged ≥55 years and <55 years was
14.7 (13.1-17.7) months and not estimable (NE) (11.0-NE) months,
respectively (Figure 1).
Twenty-four (34.8%) patients received an allogeneic hematopoi-
etic cell transplant: 18 aged ≥55 years and 6 aged <55 years. Twelve
(17.4%) patients discontinued treatment in order to receive a trans-
plant: 9 aged ≥55 years and 3 aged <55 years; 12 patients discontin-
ued treatment for other reasons and later received a transplant. After
censoring for transplant, median OS (80% CI) was 17.7 (14.5-NE)
months for all patients, 14.9 (13.4-19.3) months in patients ≥55 years
of age, and NE (NE-NE) in patients <55 years of age (Figure 1).
In patients with AML vs. MDS, the estimated median OS (80% CI)
was 16.3 (13.4-19.4) months vs. 13.0 (11.0-15.6) months (Supporting
Information Table S5). In patients with AML who were aged
≥55 years, median OS (80% CI) was 14.7 (13.1-19.3) months.
Although patient numbers were small, OS in patients aged ≥55 years,
as well as in patients aged >60 years, compared favorably with esti-
mated OS according to ELN risk criteria32: median OS (80% CI) in
patients with AML aged ≥55 years was NE (NE-NE) in those with
favorable risk, 19.3 (13.1-NE) months in those with intermediate-I risk,
13.4 (9.0-14.7) months in those with intermediate-II risk and 8.5
(5.8-12.3) months in patients categorized with adverse risk (Table 2:
Supportive Information Figure S2).
TABLE 1 Summary of proportions of patients with
investigator-reported complete remission (full analysis set), by age
group
Total ≥55 years <55 years
Total n = 69 n = 60 n = 9
CR, n (%) 32 (46.4) 24 (40.0) 8 (88.9)
80% CIa (38.7-54.1) (31.9-48.1) (75.5-100.0)
Cytogenetic risk
Good/intermediate n = 48 n = 41 n = 7
CR, n (%) 26 (54.2) 20 (48.8) 6 (85.7)
80% exact CIa (45.0-63.4) (38.8-58.8) (68.8-100.0)
Poor n = 19 n = 17 n = 2
CR, n (%) 5 (26.3) 3 (17.6) 2 (100.0)
80% exact CIa (13.4-39.3) (5.8-29.5) (100.0-100.0)
Not evaluated n = 2 n = 2 n = 0
CR, n (%) 1 (50.0) 1 (50.0) -
80% exact CIa (4.7-95.3) (4.7-95.3) -
Abbreviations: AML, acute myeloid leukemia; CI, confidence interval; CR,
complete remission; MDS, myelodysplastic syndromes. For AML, good/
intermediate cytogenetic risk = favorable, intermediate-I and
intermediate-II risk groups; poor cytogenetic risk = adverse risk group. For
MDS, good/intermediate cytogenetic risk = good and intermediate risk
groups; poor cytogenetic risk = poor risk group. CR included both con-
firmed and unconfirmed responses for MDS patients.
a Using normal approximation and CIs are expressed in percentages.
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FIGURE 1 A, Kaplan-Meier plot of OS in all patients; B, patients with AML by cytogenetic risk and C, patients aged ≥55 years with and without
censoring for patients receiving a transplant. Adv, adverse; AML, acute myeloid leukemia; CI, confidence interval; NE, not evaluable; Fav,
favorable; Int, intermediate; OS, overall survival [Color figure can be viewed at wileyonlinelibrary.com]
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3.3 | Safety
A total of 1824 AEs were reported among all 69 patients. The most
common all-causality AEs (in ≥50% of patients) were diarrhea, febrile
neutropenia, nausea and hypokalemia (Table 3). The most frequently
reported grade > 3 all-causality AEs (in ≥30% of patients) were febrile
neutropenia, anemia and thrombocytopenia; the most common nonhe-
matologic grade > 3 all-causality AEs were hypertension, pneumonia
and sepsis (n = 7 [10.1%] each). The most common treatment-related
AEs (in ≥50% of patients) were diarrhea and nausea. The most fre-
quently reported grade > 3 treatment-related AEs (≥25% of patients)
were febrile neutropenia and anemia. Median (range) investigator-
reported time to platelet recovery (≥100 000 μL) and neutrophil recov-
ery (≥1000 μL) for patients achieving CR (n = 32) was 31.0 (20-82) days
and 32.0 (3-95) days, respectively.
Across all patients, 14 (20.3%) and 25 (36.2%) patients perma-
nently and temporarily, respectively, discontinued study treatments
(glasdegib and/or cytarabine/daunorubicin) due to AEs; 5 (7.2%)
patients had dose reductions due to AEs and 35 (50.7%) patients
reported serious AEs (SAEs). The most frequently reported SAEs (≥5%
of patients) were febrile neutropenia, sepsis, and pneumonia, and all
other SAEs were reported by no more than two patients.
Over the course of the study, 41 (59.4%) deaths were reported;
5 (7.2%) treatment-emergent deaths occurred within 28 days of the
last dose: disease progression (n = 2) and sepsis, pneumonia and sep-
tic shock (n = 1 each). One case of sepsis was considered by the
investigator to be treatment-related to combination glasdegib plus
cytarabine/daunorubicin. One (1.4%) and four (5.8%) patients (all aged
≥55 years) died ≤30 and ≤60 days, respectively, from the first dose of
study treatments. No patients with CR died while on active treatment.
Thirty-six (52.2%) deaths occurred during the follow-up period
(>28 days after the last dose); the main cause among all 69 patients
was progression of the disease under study (n = 30; 43.5%).
AEs of special interests for glasdegib, including muscle spasms,
dysgeusia, alopecia, acute kidney injury, or electrocardiogram pro-
longed QTc, were nonserious; the majority were grades 1 or 2, except
for one case of serious acute kidney injury that was considered not
treatment-related. The grade 3 acute kidney injury (creatinine
2.47 mg/dL) occurred after a hypotensive episode that resolved with-
out intervention and was considered to be related to analgesics and
dehydration. On the same day, the patient was diagnosed with grade
3 acute myocardial infarction (MI); thus, the investigator considered
the acute kidney injury to be related to the non-ST-elevation MI event
TABLE 2 OS in patients with AML ≥55 years of age and aged >60 years, compared with historical controls
Total
AML cytogenetic risk
Favorable Intermediate I Intermediate II Adverse Not evaluated
Patients aged ≥55 years with AML
n 58 12 15 13 16 2
Deathsa, n (%) 36 (62.1) 2 (16.7) 9 (60.0) 10 (76.9) 13 (81.3) 2 (100)
Disease under study 29 (50.0) 1 (8.3) 7 (46.7) 10 (76.9) 10 (62.5) 1 (50.0)
Unknown 4 (6.9) 0 2 (13.3) 0 1 (6.3) 1 (50.0)
Other 11 (19.0) 1 (8.3) 3 (20.0) 2 (15.4) 4 (25.0) 1 (50.0)
Number censored, n (%) 22 (37.9) 10 (83.3) 6 (40.0) 3 (23.1) 3 (18.8) 0
Probability of survival at month 12 (80% CI)b 64.0 82.5 80.0 64.2 37.5 50.0
(55.1-71.6) (62.0-92.6) (62.6-89.9) (42.8-79.3) (22.4-52.6) (7.7-82.9)
Median OS (80% CI)c, months 14.7 NE 19.3 13.4 8.5 8.4
(13.1-19.3) (NE-NE) (13.1-NE) (9.0-14.7) (5.8-12.3) (0.5-16.3)
Patients aged >60 years with AML
n 44 9 12 11 10 2
Deathsa, n (%) 29 (65.9) 1 (11.1) 9 (75.0) 9 (81.8) 8 (80.0) 2 (100)
Disease under study 23 (52.3) 0 7 (58.3) 9 (81.8) 6 (60.0) 1 (50.0)
Unknown 3 (6.8) 0 2 (16.7) 0 0 1 (50.0)
Other 10 (22.7) 1 (11.1) 3 (25.0) 2 (18.2) 3 (30.0) 1 (50.0)
Number censored, n (%) 15 (34.1) 8 (88.9) 3 (25.0) 2 (18.2) 2 (20.0) 0
Probability of survival at month 12 (80% CI)b 62.4 88.9 75.0 60.6 30.0 50.0
(52.1-71.1) (65.4-96.8) (54.6-87.2) (38.3-77.0) (13.4-48.7) (7.7-82.9)
Median OS (80% CI)c, months 14.5 NE 15.7 13.4 8.5 8.4
(13.0-17.7) (NE-NE) (13.0-19.4) (7.9-13.7) (4.0-9.7) (0.5-16.3)
Historical controlsd (n = 710)32
Median OS (95% CI), months 8.7 14.6 9.5 9.2 4.8 -
(7.8-9.7) (11.7-17.6) (7.3-11.7) (7.1-11.3) (3.7-5.9)
Abbreviations: AML, acute myeloid leukemia; CI, confidence interval; NE, not estimable; OS, overall survival.
a Patients may have multiple reasons for cause of death.
b Calculated from the product-limit method.
c Based on the Brookmeyer and Crowley method.
d Treatment with 7 + 3 schedule.
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together with severe hypotension. Muscle spasms led to permanent
discontinuation of glasdegib in one patient. No clinically significant
glasdegib-related QTc prolongation was observed.
3.4 | Pharmacokinetics
In all, 65 of 69 patients enrolled in the study provided glasdegib
plasma concentration data. Forty-two patients were considered to be
dose compliant and did not receive cytochrome P450 (CYP)3A4 inhib-
itors around the time of PK sampling (which might have influenced
glasdegib exposure), and provided steady-state Ctrough parameter data
on cycle 1 day 10. The observed glasdegib steady-state Ctrough geo-
metric mean value was 308.7 ng/mL (geometric % coefficient of vari-
ance, 74%).
3.5 | Mutational analyses
Fifty patients were included in baseline mutational analyses of bone
marrow and/or peripheral blood with relationship to response. No sig-
nificant associations were evident between mutational status of any
of the 12 genes analyzed and clinical response (Supporting Informa-
tion Table S6).
4 | DISCUSSION
This was a phase 2, open-label, international, multicenter, safety and
efficacy study wherein glasdegib was administered in combination
with cytarabine/daunorubicin in previously untreated patients with
AML or high-risk MDS. Although the primary objective of demonstrat-
ing a ≥54% CR rate in patients aged ≥55 years was not achieved, the
response rate of 46.4% (80% CI 38.7-54.1) for all patients was within
the range of those reported for other AML therapies (19-76%, with
most values ~40-50%).2,3,32,34–41 This result included CR rates
reported for patients with AML who received standard doses of cytar-
abine/daunorubicin on the 7 + 3 schedule.4,42 However, comparisons
between trials are limited due to differences in study design and
patient populations, as well as the effect of age and AML risk category
on CR rates.4
Glasdegib in combination with cytarabine/daunorubicin has the
potential to demonstrate improved OS in patients with AML or high-
risk MDS. Median OS of 14.9 months was achieved with glasdegib
100 mg combined with cytarabine/daunorubicin in the overall patient
population and was within the range for OS (6.5-24.5 months)
reported in the literature for patients treated with other AML treat-
ment regimens, including a trial of high-dose daunorubicin in older
patients with AML.2–5,32,34,37,38,40–43 Despite the limited sample sizes,
in a post hoc analysis, the median OS compared favorably with histori-
cal controls across ELN risk groups.3,32,40–42
Around 24 months, the OS curve for patients 55 years or older
began to plateau and extended to 36 months. These results suggest
that patients who reached this time point (~40% of patients) had a
low risk of death thereafter, which may indicate that a subpopulation
of patients in particular derived a survival benefit from glasdegib treat-
ment. The survival benefit does not appear to be influenced by trans-
plantation, given that OS results with and without censoring for
patients who underwent transplant were similar. Longer follow-up
TABLE 3 Treatment-emergent all-causality adverse events reported in ≥30% patients (safety analysis set)
n (%) Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 Total
Any adverse event 0 1 (1.4) 11 (15.9) 52 (75.4) 5 (7.2) 69 (100.0)
Diarrhea 30 (43.5) 18 (26.1) 1 (1.4) 0 0 49 (71.0)
Febrile neutropenia 0 0 42 (60.9) 2 (2.9) 0 44 (63.8)
Nausea 20 (29.0) 18 (26.1) 2 (2.9) 0 0 40 (58.0)
Hypokalemia 19 (27.5) 9 (13.0) 8 (11.6) 1 (1.4) 0 37 (53.6)
Pyrexia 21 (30.4) 9 (13.0) 3 (4.3) 1 (1.4) 0 34 (49.3)
Constipation 23 (33.3) 9 (13.0) 0 0 0 32 (46.4)
Anemia 0 2 (2.9) 26 (37.7) 0 0 28 (40.6)
Decreased appetite 15 (21.7) 10 (14.5) 1 (1.4) 0 0 26 (37.7)
Fatigue 9 (13.0) 13 (18.8) 3 (4.3) 0 0 25 (36.2)
Vomiting 20 (29.0) 5 (7.2) 0 0 0 25 (36.2)
Hyponatremia 16 (23.2) 0 8 (11.6) 0 0 24 (34.8)
Thrombocytopenia 0 1 (1.4) 3 (4.3) 19 (27.5) 0 23 (33.3)
Abdominal pain 11 (15.9) 9 (13.0) 2 (2.9) 0 0 22 (31.9)
Headache 11 (15.9) 9 (13.0) 2 (2.9) 0 0 22 (31.9)
Hypocalcaemia 5 (7.2) 12 (17.4) 5 (7.2) 0 0 22 (31.9)
Edema peripheral 18 (26.1) 4 (5.8) 0 0 0 22 (31.9)
ALT increased 16 (23.2) 1 (1.4) 3 (4.3) 1 (1.4) 0 21 (30.4)
Chills 13 (18.8) 8 (11.6) 0 0 0 21 (30.4)
Safety analysis set included all enrolled patients who received at least one dose of any of the study medications. Patients were counted only once per pre-
ferred term in each row. Each count was based on the maximum grade of events. MedDRA (version 19.1) coding dictionary applied. Adverse events were
graded in accordance with National Cancer Institute CTCAE version 4.03.
Abbreviations: ALT, alanine aminotransferase; MedDRA, Medical Dictionary for Regulatory Activities; CTCAE, Common Terminology Criteria for Adverse
Events.
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and, particularly, randomized trials are required to better assess the
possible effect glasdegib may have in improving OS. Responses were
observed across diverse mutational profiles, suggesting the potential
for broad efficacy of glasdegib in combination with cytarabine/
daunorubicin.
The primary endpoint, CR rate 54%, was based on the CR rate of
cytarabine/daunorubicin alone, adapted from Burnett et al.44 Given
the unique mechanism of action of glasdegib as an inhibitor of SMO,
traditional endpoints such as CR or CR/CRi rate may underestimate
its clinical benefit. For example, preclinical studies have shown that
SMO inhibitors have little direct cytotoxicity on bulk AML blasts and
would therefore not be expected to have a large effect on CR
rates.45,46 If glasdegib eliminated AML stem cells, one would expect
the effect to be primarily on relapse rate and OS. Indeed, despite the
small patient numbers in this trial, there was encouraging evidence of
potentially prolonged OS with glasdegib compared with historical
data. Although the response duration was short in this analysis, it was
impacted by patients who discontinued treatment due to transplant
and, because disease status was not collected during survival follow-
up, it was also derived by censoring patients at the end of treatment
(even those in CR, CRi, MLFS); therefore, the most conservative calcu-
lations were used.
Skin has been typically used to measure the pharmacodynamics
of SMO inhibitors and glasdegib 100 mg once daily as monotherapy
was previously associated with Hh pathway knockdown of >80% in
skin.47 In the current study, assessment of the effects of glasdegib on
Hh pathway-dependent transcripts such as GLI1 and GLI2 in blood
was attempted, but proved infeasible because baseline expression
was undetectable in most patients (data not shown). Hence, a limita-
tion of this study is the lack of specific data demonstrating modulation
of Hh target genes in AML blasts or AML stem cells. Hh ligands are
secreted proteins; therefore, any combination of autocrine and/or
paracrine signaling between tumor and stroma would be susceptible
to modulation by glasdegib.48 Recent reports have implicated Hh sig-
naling in the bone marrow stem cell niche as a primary mediator of
chemoresistance, suggesting an alternative mechanism of action for
glasdegib in AML.49,50
The combination of glasdegib with cytarabine/daunorubicin
was well tolerated, with a safety profile consistent with those
observed in patients with AML receiving intensive chemother-
apy.1,3,5,34,36,37,40,51,52 Additionally, the AEs observed with glas-
degib in combination cytarabine/daunorubicin were similar to
those reported for glasdegib in combination with LDAC,26 as well
as other SMO inhibitors, and the majority of muscle spasms, dys-
geusia and alopecia AEs were grades 1 or 2.53–55 The most fre-
quently reported grade > 3 treatment-related AEs were febrile
neutropenia and anemia, with the time to hematologic recovery
in line with that previously reported in the literature for patients
with AML who received cytarabine/daunorubicin on the 7 + 3
schedule.3 No new safety signals were detected.
Long-term management of SMO inhibitor-related toxicities has
been evaluated with visomdegib and sonidegib in patients with
advanced basal cell carcinoma.56,57 The use of dose adjustments and
interruptions to manage AEs have contributed to long treatment
exposures and sustained clinical responses for these agents.56,57
Therefore, it will be critical to evaluate the long-term safety of glasde-
gib and potentially apply similar strategies for AE management in
patients with AML or high-risk MDS.
Although this phase 2 study is limited by small patient numbers
and will require validation in a larger prospective trial, the results from
this study are encouraging. Glasdegib in combination with cytarabine/
daunorubicin was well tolerated and was associated with clinical activ-
ity in untreated patients with AML or high-risk MDS, as reflected by
potential prolongation of OS in the context of historical controls
across all risk groups. CR rates matched historical controls; however,
low rate of relapse and a suggestion of a favorable OS observed in the
current study suggest that the antileukemia effect of glasdegib may
be primarily mediated through the elimination of AML stem cells. To
confirm this mechanism, future studies should evaluate the effect of
glasdegib on MRD-positive disease in the post-remission setting. A
randomized phase 3 trial of glasdegib in combination with chemother-
apy on a 7 + 3 schedule is ongoing.
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